Related Experiment Video

Updated: Mar 28, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.8K

USE OF RECOMBINANT ACTIVATED FACTOR VIIa IN A-SIX-MONTH-OLD CHILD DUE TO MASSIVE HEMORRHAGE DURING ELECTIVE SURGERY

Alenka Spindler Vesel, Vesna Novak-Jankovič, Branka Maldini

    Acta Clinica Croatica
    |December 16, 2015
    PubMed

    Insights

    Recombinant activated factor VIIa (rFVIIa) effectively controlled massive bleeding in an infant undergoing surgery for choroid plexus carcinoma. This treatment achieved good hemostasis without causing adverse thromboembolic events.

    Area of Science:

    • Pediatric Surgery
    • Hematology
    • Oncology

    Background:

    • Choroid plexus carcinoma is a rare brain tumor in infants.
    • Massive bleeding and coagulation disturbances are significant surgical risks.
    • Recombinant activated factor VIIa (rFVIIa) is a hemostatic agent used for bleeding disorders.

    Observation:

    • A 6-month-old infant with lateral ventricle choroid plexus carcinoma experienced massive intraoperative bleeding.
    • Coagulation disturbances complicated the surgical management.
    • rFVIIa was administered to address the severe hemorrhage.

    Findings:

    • The administration of rFVIIa led to effective hemostasis.
    • No intraoperative or postoperative thromboembolic complications were noted.
    • rFVIIa proved beneficial in managing surgical bleeding in this pediatric case.

    Implications:

    • rFVIIa can be a valuable therapeutic option for managing massive bleeding during pediatric neurosurgery.
    • This case highlights the safety and efficacy of rFVIIa in young infants with complex surgical challenges.
    • Further research may explore rFVIIa's role in other pediatric surgical bleeding scenarios.

    More Related Videos

    Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay13:08

    Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

    Published on: September 9, 2012

    19.5K
    A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

    A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

    Published on: June 4, 2021

    3.7K

    Related Concept Videos

    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    465
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    2.3K
    Extrinsic and Intrinsic Pathways of Hemostasis01:20

    Extrinsic and Intrinsic Pathways of Hemostasis

    Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
    The Extrinsic Pathway
    The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
    15.3K
    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
    2.7K
    Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

    Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

    Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
    656
    Clot Retraction and Fibrinolysis01:16

    Clot Retraction and Fibrinolysis

    After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
    10.2K